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Objective: Use of statins in prevention of ath-
erosclerosis is effective but expensive. Patient se-
lection gains wider public attention as medication
costs in the US and Europe augment by 8% to 10%
per year. We examined different clinical risk strat-
ification strategies, particularly focusing on echo-
cardiographic atherosclerosis quantification, for
their impact on event reduction and cost-effective-
ness in statin treatment.
Methods and Results: In a prospective, consecu-
tive cohort of 336 patients referred to non-invasive
cardiac examination, risk stratification was done 
by various combinations of risk factors and non-
invasive atherosclerosis quantification. Atheroscle-
rotic burden was determined through measuring
“aortic elastance” by transthoracic echocardiogram,
a validated non-invasive method. Cardiovascular
events were recorded at a mean follow-up of one
year. Echocardiographically determined athero-
sclerosis severity and event history, especially in
combination, yielded the best selection strategies
for statin treatment over a broad range of prede-
termined funding or required event reductions,
surpassing conventional cardiovascular risk fac-
tors. From 26.8 statin-preventable events/1000 pa-
tients/year (assuming all patients treated), the best
selection strategies could avoid: 24 with 66% of 
the cost for statin treatment (atherosclerosis and
age criteria), 20.1 with <50% of the budget, 12.2
with <30% of the budget or 9.6 with <15% of the
budget (using combinations of atherosclerosis and
prior events), while conventional strategies with-
out echo quantification of atherosclerosis were in-
ferior.
Conclusion: Non-invasive echocardiographic
quantification of atherosclerosis improves effi-
ciency and cost-effectiveness in statin treatment. 
Key words: echocardiography; atherosclerosis; cost-
effectiveness; statin; stratification
Echocardiographic quantification 
of atherosclerosis leads to cost-effective 
treatment with statins
Data from a prospective study of 336 patients
Fabian Nietlispacha, Balthasar Hugc, Christian Jansenb, Vânia Barbosaa, Dagmar Kellera, Peter T. Busera,
Martin Siegemundb, Stephan Marschb, Patrick R. Hunzikerb
a Divison of Cardiology, University Hospital Basel, Switzerland
b Medical Intensive Care Unit, University Hospital Basel, Switzerland
c Department of Internal Medicine, University Hospital Basel, Switzerland
Atherosclerosis and its complications such as
myocardial infarction, stroke and peripheral vas-
cular disease are leading causes for morbidity and
mortality in western countries. Primary and sec-
ondary prevention have shown to be effective, in-
cluding life-style changes and/or pharmacological
prevention [1–6]. Trials like AFCAPS/TexCAPS
[1] and ASCOT-LLA [2] showed that statin treat-
ment is effective in large populations. Although
prevention by life-style changes is inexpensive and
desirable, it is, as an isolated measure, often not
sufficient to reduce cardiovascular risk to a desired
level. Therefore, treatment with statins is an impor-
tant issue, even though such treatment is expensive
and drugs may have to be taken over many years.
In times of restricted resources, it is important
to distribute them as effectively as possible. Cost-
effectiveness of lipid-lowering therapies is thus an
ongoing debate [7]. To answer the questions which
patients will profit most from statin treatment, to
what extent lipid lowering should be administered
in the general population and how cost-effective-
ness can be improved, additional stratification
methods are needed.
Summary
Introduction
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Conventionally, statin therapy is initiated in
patients with prior events, hyperlipidemia or other
risk factors, or a high risk score computed in vari-
ous ways (eg, Framingham risk score, which takes
in account gender, age, total cholesterol, HDL-
cholesterol, smoking and systolic blood pressure;
or, for european males below the age of 65, the
PROCAM algorithm).
Thus, high-risk constellations used for strati-
fication typically ignore the actual extent of the
atherosclerotic process itself, the sine qua non for
atherosclerotic complications. This process plays
only a small role in the actual risk stratification,
because measurement of atherosclerosis severity
has technically been difficult. However, there have
been recent advances in non-invasive determina-
tion of atherosclerosis severity, which now can be
done as a bedside investigation with standard
echocardiographic equipment and with proven
prognostic implications [8].
We hypothesised that direct echocardio-
graphic quantification of atherosclerosis will im-
prove patient selection and thus cost-effectiveness
of statin treatment because it is directly linked to
the fundamental pathophysiological process, com-
pared to the classical “risk factors” which are only
indirectly linked to cardiovascular events through
the intermediary of atherosclerosis (figure 1).
Thus, we analysed data from a prospective cohort
study that analysed techniques of non-invasive ath-
erosclerosis quantification [8], focussing here on
the selection of cost-effective risk stratification
strategies.
Methods
The study was designed to test the usefulness of dif-
ferent methods of cardiovascular risk stratification. Spe-
cial emphasis was put on statin treatment in order to find
different levels of cardiovascular risk and financial expen-
diture as well as the absolute and relative number of events
that can potentially be avoided with statin treatment.
Study design
In a consecutively collected study cohort of patients
referred for non-invasive cardiovascular assessment to
three centres, the severity of atherosclerosis was measured
non-invasively, conventional risk factor assessment was
done, and the occurrence of major cardiovascular events
was monitored for one year. The predictive value for major
adverse cardiovascular events of conventional risk factors
and of non-invasive atherosclerosis quantification in this
cohort was analysed as reported in a separate paper [8].
Based on observed cardiovascular event rates in subgroups
as well as on actual statin intake, a statistical model was
then designed that allowed studying the impact on major
cardiovascular events of statin treatment in different sub-
groups (see below). A number of different stratification
strategies were then applied to this cohort model to assess
the impact on event reduction. 
Observed and modelled event risk
Based on actual observed cardiovascular events and
actual statin intake, as well as on relative risk reduction
data from the statin megatrials, the number of avoidable
events was calculated for the subgroup not on statins, and
the number of avoided events was calculated for the sub-
group that was on statin treatment. This is reasonable be-
cause relative risk reduction in most subgroups of the statin
megatrials was similar, even when absolute risk reducation
varied significantly due to marked differences in absolute
risk in different groups in those studies. This constant rel-
ative risk reduction allows calculation in treated patients
of the expected number of additional events without treat-
ment and vice versa as shown in the text box.
Relative risk reduction under statin treatment was ex-
pected to be 33.3%, because primary prevention trials had
shown relative risk reductions between 30% and 37%
[1–3, 9] corresponding to relative risk in treated patients
of 66.6% (63 to 70); and secondary prevention trials had
shown relative risk reductions in a comparable range [6].
Atherosclerosis severity
Atherosclerosis severity was measured non-invasively
using a recently described transthoracic echocardio-
graphic approach [8] which uses specific aortic elastance
as surrogate parameter for overall atherosclerosis severity.
This parameter can be measured easily with limited time
consumption using standard echocardiographic equip-
ment. The method has been validated by direct visualisa-
tion of plaque burden, is robust when assessed against a
broad range of possible confounding factors, has proven
to be a powerful cardiovascular risk predictor, and is com-
petitive compared to other methods that exploit arterial
mechanics [10–16]. Briefly, measurement of atherosclero-
sis severity is based on the biomechanics of pulse wave
propagation in the central arterial tree described by the
Moens-Korteweg equation.
The product E*h, termed “specific aortic elastance”
is increased when either wall thickness is increased (eg, due
to plaque formation) or when the wall becomes stiffer due
to fibrosis or calcium deposition. Specific elastance has
been shown to correlate strongly with plaque burden. As
described in detail in the validation paper, vessel diameter
was measured as an average of three measurements at
three aortic locations; aortic length was calculated as 0.41
m/m body height; blood density can be considered con-
stant (1060 kg/m3) and pulse wave velocity was determined
from wavefront delay from the left ventricular outflow
tract to the femoral artery in the groin. In practice this
means that aortic diameters are measured in the ascend-
ing aorta, the aortic arch and in the subxiphoidal window
are measured by 2D echo and are averaged, yielding D.
Then pulse wave delay relative to the ECG R-wave is
measured in the left ventricular outflow tract and in the
groin, and the difference of these delays taken as wave
propagation time; this is divided by aortic length to yield
wave velocity c. Finally, these measurements are substi-
tuted in the formula for Specific Elastance E*h derived from
above: 
c = wave propagation velocity
h = wall thickness
rf = fluid density
D = vessel diameter
E = Young’s Module
E * h
c2 = with
rf * D
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Number of patients: 336
Gender 206 Men (61%), 
130 Women (39%)
Age (mean): 63 years  (SD 15, range 11–92)
1st tertile <59.6 yrs
2nd tertile 59.6 –70.5 yrs
3rd tertile >70.5 yrs
Risk factors:
Hypercholesterolaemia: 203 (60%)
Smoking: 87 (26%)
Positive family history: 61 (18%)
Diabetes: 49 (15%)
Hypertension: 143 (43%)
LV Hypertrophy: 49 15%
Number of risk factors 1.4 (SD 1.1)
0 risk factors 26%
1 risk factor 34%
2 risk factors 22%
3 risk factors 14%
≤4 risk factors 4%
LVEF (mean): 54% (SD 14)
Below 50%: 22%
Prior myocardial infarction: 62 (18%)
Prior Stroke: 32 (10%)
Prior arterial revascularisation: 44 (13%)
Blood lipids:
Mean cholesterol 5.3 (SD 1.2) mmol/l
Mean HDL 1.3 (SD 0.41) mmol/l
Mean LDL 3.3 (SD 1.0) mmol/l
Patients on Statin Therapy: 39 (12%)
Table 2
Patient characteristics. 
A simple web-based atherosclerosis calculator for the
formula given above as well as reference values can be
found at http://www.koronarsyndrom.ch.
Risk factors and scores
According to current clinical practice, demographic
data were assessed and a history of known cardiovascular
risk factors was taken, taking into account the variables
total cholesterol, HDL-cholesterol, diabetes, smoking
and hypertension, while minor risk factors like homocys-
tein levels and lipoprotein fractions (other than choles-
terol and HDL-cholesterol) were neglected according to
current clinical practice. A detailed history of cardiovas-
cular events and procedures was taken, relying on patient
and physician interviews in combination with hospital
chart reviews. An untreated total cholesterol of >6.5
mMol/l, an untreated total cholesterol >5.2 mMol/l with
a total cholesterol to HDL Ratio of >5 defined hypercho-
lesterolaemia according to the guidelines in effect at the
initiation of the study. As risk scores, the number of major
risk factors and the Framingham score [17] were chosen
because of their widespread clinical application. The
Framingham score takes into account gender, age, total
cholesterol, HDL-cholesterol, smoking and systolic blood
pressure; it correlates with the ten year risk of coronary
artery disease (CAD). As a European alternative, the
PROCAM score could have been used, but was not cho-
sen because only 120 of our 336 patients matched the
PROCAM inclusion criteria (males ≤65 years). 
Patients
Included were 336 consecutive patients referred for
non-invasive cardiological examination. Exclusion criteria
were manifest arterial obstructive disease of the aorto-
iliacal axis (due to the evident limitation of measuring
“wave propagation” across a vessel occlusion) and missing
consent. Patients underwent echocardiographic quantifi-
cation of atherosclerosis as described above. Follow-up at
one year was done by telephone interview of patients and
treating physicians and hospital chart review in case of
events. The primary endpoint was a composite endpoint
of atherosclerotic death, myocardial infarction, or stroke.
To yield an additional age corrected measure of atheroscle-
rosis severity, analyses were also performed after dividing
the cohort into three age strata. 
Treatment scenarios
A range of treatment scenarios was chosen with the
aim to cover current practice, as well as to cover very lib-
eral (all patients treated) as well as very stringent treatment
E*h = rf *D*2 = 1060* diameter*
propagation-time
0,41* height
2
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Figure 1
Direct vs indirect
stratification for
statin treatment.
Conventional risk
stratification gives
little weight to actual
determination of ath-
erosclerosis severity.
As atherosclerosis
severity can be meas-
ured non-invasively
by echocardiography,
this study examines
whether this meas-
urement can be prof-
itably used for cost-
efficient patient
selection for statin
treatment.
atherosclerosis severity (highest tertile) (110 pts)
atherosclerosis severity (highest and middle tertile) (221 pts)
age-corrected atherosclerosis severity 
(highest and middle tertile) (220 pts)
prior event or for atherosclerosis severity 
(highest tertile) (158 pts)
prior event and atherosclerosis severity (highest tertile) (39 pts)
hyperlipidaemia and atherosclerosis severity 
(highest and middle tertile) (134 pts)
prior event and atherosclerosis severity 
(highest and middle tertile) (63 pts)
prior event (88 pts)
hyperlipidaemia (203 pts)
Framingham risk score >12.9 (107 pts)
>1 risk factor (133 pts)
>2 risk factors (59 pts)
highest tertile for age (110 pts)
prior event AND hyperlipidaemia (63 pts)
all treated (336 pts)
Table 1
List of different
stratification scenar-
ios and number of
patients included 
in each scenario 
(pts = patients fulfill-
ing the criterion).
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Figure 2
Relationship between the fraction of patients treated with a
particular stratification scenario, compared to absolute
event reduction. Diamonds mark strategies that make use of
echo-quantification of atherosclerosis. For a given drug
budget for the cohort (ie, a given prescription frequency)
that can be chosen on the X-axis, the number of avoidable
events using different stratification scenarios can be found
on the Y-axis. The diagonal line corresponds to random
sampling of the cohort. 
Results
A total of 336 patients were included; patient
characteristics are given in (table 2). Median spe-
cific aortic elastance was 1.8 kN/m (interquartile
width: 1.5; range: 0.2 to 23 kN/m) in the entire co-
hort and 2.1 kN/m in statin-treated patients. Strat-
ification into three tertiles yielded cutoff values of
1.43 kN/m and 2.33 kN/m, respectively, for the
lowest, middle, and highest tertile of atherosclero-
sis severity.
Follow-up was done in 99.7% of patients with
one patient lost because of emigration to another
continent. Including multiple events in individual
patients, a total of 21 deaths occurred (9 were non-
atherosclerotic deaths), 5 nonfatal myocardial in-
farctions and 7 strokes were observed and 21 revas-
cularisation procedures were performed (8 coro-
nary revascularisations, 10 bypass operations, 3
carotid interventions); events occurred in 10.3% 
of patients on statins and in 12.1% of untreated
patients. 
Counting only one endpoint per patient, the
predefined primary composite endpoint of athero-
sclerotic death, nonfatal infarction or cerebrovas-
cular stroke was reached in a total of 22 patients. 
As reported in detail in [8], specific elastance
was a strong predictor of the primary endpoint 
(p = 0.0002) with a 16-fold increase in relative risk
from the lowest to the highest atherosclerosis ter-
tile [8] (figure 5), supporting the results of the val-
idation study [8] where specific elastance was the
best correlation of the non-invasively measured
parameters with directly imaged plaque burden 
(R2 = 0.76; p <0.0001).
The different calculated stratification scenar-
ios are shown in figures 2 and 3. Figure 2 shows
the relationship between the percentage of pa-
tients treated with the particular stratification sce-
nario, compared to absolute event reduction per
1000 patients treated for one year. Diamonds mark
strategies that make use of echo-quantification of
atherosclerosis. Generally, adding non-invasive
atherosclerosis quantification shifted the strategy
towards the upper left in the graphs indicating
higher effectiveness at lower cost.
The best number needed to treat to avoid one
event was reached in group E combining prior car-
diovascular events with severe atherosclerosis, cor-
responding to the lowest costs per event avoided
are least in this group, although the absolute event
reduction was limited in this group because more
criteria. The different stratification scenarios are seen in
(table 1). The first seven scenarios include echo quantifi-
cation stratification. Scenario A selects a high risk popu-
lation, compared to scenario B and C where patients at
moderate risk are also selected. Combinations of athero-
sclerosis severity with a history of prior cardiovascular
events are evaluated in scenario D and E. Taking two pa-
rameters into account seems realistic and practicable for
daily practice. The same is true for the scenario F, where
hyperlipidaemia instead of prior events is used in combi-
nation with atherosclerosis severity. Scenario G evaluates
a larger proportion of patients, also including patients with
moderate atherosclerosis. More conventional stratifica-
tion methods are evaluated in scenarios H to O, and for
reference, statin treatment of the whole cohort is de-
scribed in scenario P. 
The number needed to treat (NNT) per avoided
event can then be calculated from the difference between
the number of events if both subgroups were treated with
statins and the number of events if no subgroup was
treated with statins, divided by the number of events. Drug
costs per avoided event were computed by multiplying
NNT with the costs for statin treatment for one year.
Drug costs were taken from average end user prices for
statins in typical doses in Switzerland, which amounted to
560 Euros per patient and year of statin treatment (com-
pared to 217 Euros for a transthoracic echocardiogram)
Statistics
Statistics were done using StatView Software 5.01
(Abacus Inc., Berkeley, California). Data were evaluated
for normal distribution. If a normal distribution was
found, standard deviation (SD) and mean were used, oth-
erwise median and interquartile width are given. Because
the surrogate parameter for atherosclerosis severity, spe-
cific elastance did not show normal distribution, data were
log transformed for analysis. Event risk was calculated for
tertiles of different predictors of cardiovascular events.
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Figure 3
How many events can be avoided at what cost? Impact 
of different patient selection strategies for statin treat-
ment. Diamonds mark strategies that make use of echo-
quantification of atherosclerosis. An optimal strategy
yields a maximum absolute event reduction at a minimal
cost, ie, it is found in the upper left of the diagram, while
ineffective selection strategies have a small impact on
overall event rate, but have a large cost per avoided event
(lower right). Note that strategies that include atheroscle-
rosis measurement tend to the upper left, an observation
valid for multiple spending levels.
Patients treated Absolute event reduction / NNT/ event avoided Drug costs per avoided 
1000 patients / year event (Euro)
A Atherosclerosis severity 15.6 (13.8–17.6) 21.2 (18.7–23.9) 11864
[highest tertile] 
B Atherosclerosis severity 22.8 (20–25.6) 29 (25.9–33) 16229
[highest & middle tertile]
C Age-corrected atherosclerosis severity 24 (19.4–27.7) 27.5 (23.8–34) 15389
[highest & middle tertile]
D Prior event OR atherosclerosis severity 20.1 (18–23.2) 23.6 (20.5–26.7) 13207
[highest tertile] 
E prior event AND atherosclerosis severity 8.1 (7.1–9) 14.5 (13–16.5) 5760
[highest tertile]
F hyperlipidaemia AND atherosclerosis severity 18.5 (16–21.6) 21.6 (18.6–25) 12088
[highest and middle tertile] 
G prior event AND atherosclerosis severity 12.2 (11.2–14.8) 15.4 (12.8–16.9) 8618
[highest or middle tertile]
H prior cardiovascular event 14.1 (11.6–15.8) 18.7 (16.7–22.8) 10465
I hyperlipidaemia 18.9 (16.6–21.3) 31 (27.1–35) 17348
K Framingham risk score >12.9 9.3 (8.5–10.6) 34.3 (30.4–37) 19195
L >1 risk factor 13.5 (11.9–15.4) 29.6 (25.9–33.7) 16564
M >2 risk factors 9 (7.7–10.1) 19.7 (17.5–22.9) 11024
N highest tertile for age 14.4 (12.6–16) 23 (20.6–26.1) 12871
O prior cardiovascular event AND 11.7 (10–13.1) 16.4 (14.4–19) 9178
hyperlipidaemia
P all treated 26.8 (16.6–32.6) 37.3 (31–41) 20873
Table 3
Absolute event
reduction, number
needed to treat and
drug cost per
avoided event for
each stratification
scenario. Calculation
with 33.3% expected
risk reduction by
statins, (brackets:
range for expected
risk reduction by
statins of 30% and
37%, respectively).
NNT = Number
needed to treat. 
cumulative events occurred in the much larger pro-
portion of patients at moderate risk. Compared to
treatment of all patients, withholding of statins of
those in the low atherosclerosis tertile still pre-
vented most events. 
Table 3 summarises the results of the different
treatment strategies in a side by side view.
Figure 3 observes the data from a different
point of view: how much do I want to spend to
avoid one event, and how many events can be
avoided overall with a given strategy? Again, it was
seen that combination of atherosclerosis quantifi-
cation methods shifted the curve to the upper left,
again indicating “low cost – high effectiveness”. 
The question of patient selection for preven-
tion of atherosclerosis is of prime importance, first
because a large proportion of our population will
develop atherosclerotic disease and will eventually
die from it, and second, because widespread, unfo-
cused statin medication carries the risk of breaking
our public healthcare systems due to the significant
price tag of these drugs. Optimal prevention
strategies will therefore not only give those at high
risk an optimal benefit, but will also allow spend-
ing the healthcare budget wisely, so that the
healthcare system can afford to treat them at all.
The present study highlights that the presence
and extent of atherosclerosis is not only of patho-
Discussion
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physiological importance for development of ath-
erosclerotic complications, but atherosclerosis
severity can also be evaluated non-invasively at the
bedside; such measurement can profitably be used
for selection of an optimal cardiovascular preven-
tion strategy, independent from the desired risk
threshold chosen or from the budget one is willing
to spend per avoided event. 
Evidently, those patients who have already suf-
fered a manifestation of atherosclerosis are at high
risk by this simple fact (although even in this pop-
ulation, underlying atherosclerosis severity still
matters), but the overall impact on event number
remains limited because many events occur in a
population at moderate risk. More important is the
question, which additional “risk factors” should be
taken into account for prevention in those who
have not yet suffered an event. In view of the ever-
growing number of statistically significant risk fac-
tors (often detectable only in very large databases),
simple algorithms for individualised treatment de-
cisions, which are nevertheless as powerful as pos-
sible, are needed to render this approach practica-
ble. This study argues that atherosclerosis severity
itself is not only a key variable in the pathogenetic
process and therefore in predicting individual risk,
but is also helpful for choosing an appropriate
treatment decision in an individual person. 
While the recognition of hypercholesteraemia
as a risk factor [18] and observation of risk reduc-
tion through lowering of a pathologically high
cholesterol level [6] made this measurement of
prime importance for initiation of statins in earlier
years, today, the awareness that statin effects are
quite independent from plasma cholesterol [2, 4,
19] together with the recognised pleiotropic statin
effects [20] have led to less reliance on plasma cho-
lesterol alone for initiating statin treatment. In
addition to patient history and conventional risk
factors, a range of tests is available that attempt 
to stratify risk by assessing atherosclerosis severity.
They include ultrasound methods like measure-
ment of carotid intima-media thickness, strongly
advocated by some [21], while others doubt its
value in the individual [22]. Other methods are
based on calcium detection by computed tomog-
raphy [23–25] – a method associated with radiation
exposure which is not undisputed, while magnetic
resonance imaging is also able to visualise athero-
sclerosis [26, 27] without radiation, but at a cost
that renders applicability in a general population
questionable. Studies that compare the usefulness
of such methods head-to-head will certainly be im-
portant in the future.
The echocardiographic method used for ath-
erosclerosis quantification in the present study is
not the only one that is based on central arterial
mechanics [10–16]. We prefer it to others because
it has not only a strong basis in biophysics but has
also been validated by direct visualisation of plaque
burden, has proven powerful in risk prediction [8],
can be performed by a physician experienced in
echocardiography in a minimum of time, and does
not need additional equipment.
There are also limitations to this study: al-
though based on actual outcomes in a multicentre
setting, this is not a randomised trial; such a large,
randomised trial would be welcome, but for a tech-
nique that does not widen the indications for a
drug but rather focuses drug use, the financing
would be difficult. The fact that a cohort referred
for non-invasive cardiological examination was
studied represents bias, and results can therefore
best be applied to similar groups of individuals;
more data in other patient groups are needed (cur-
rently such studies are ongoing, as are studies with
a longer follow up). Another limitation is the use
of same relative risk reduction with statin treat-
ment for all patients, a finding that has been con-
firmed in most subgroups in the statin megatrials,
but not in all [1, 5]. Full cost effectiveness calcula-
tions might also include costs incurred by physi-
cian visits and laboratory tests as well as costs saved
through avoided events [28], as well as indirect
costs, although this would not weaken the key mes-
sage of this paper, namely that improved targeting
of the use of an expensive drug will improve cost-
effectiveness. Finally, larger cohorts/longer obser-
vation periods with more events are desirable to
render calculations more robust.
Clinical implementation of echocardiographic
atherosclerosis quantification in view of statin pro-
phylaxis appears straightforward as the necessary
equipment for the simple technique is widely avail-
able, an echocardiographic examination is less than
half as costly as statin treatment for one year, and
the examination yields additional prognostic infor-
mation such as left ventricular hypertrophy, left
ventricular ejection fraction as well as informa-
tion about the presence of an abdominal aortic
aneurysm, all of which may have therapeutic con-
sequences.
We conclude that cost-efficiency of athero-
sclerosis prevention by statin treatment can be op-
timised by non-invasive, echocardiographic quan-
tification of atherosclerosis. 
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